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The aryl hydrocarbon receptor (AHR) is a ligand-activated
member of the bHLH-PAS family of transcription factors.
Members of this family include HIF1a, EPAS, and SIM, which
are involved in hypoxia and nervous system development.
Another member of this family, aryl hydrocarbon nuclear
translocator (ARNT), is the dimerization partner for the AHR.
The AHR is often classiﬁed as a sensor of a wide range of
xenobiotics, leading to induction of xenobiotic metabolism
through enhanced expression of phase I/II enzymes. The
environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) is a prototypic ligand for the AHR and is
often used to study the effects of prolonged AHR activation.
Rodent exposure to TCDD results in a plethora of toxic effects,
including wasting syndrome, tumor promotion, developmental
defects, and liver toxicity (reviewed in Vanden Heuvel and
Lucier, 1993). The key target genes that lead to these toxic end
points are largely unknown. AHR activation can occur through
a growing list of chemicals that appear to be structurally
diverse and include many polycyclic aromatic hydrocarbons,
tryptophan metabolites, and ﬂavones (Denison and Nagy,
2003). Soluble receptors such as the AHR could possibility alter
transcription of target genes through several distinct mecha-
nisms. The work of Bunger and coworkers (Bunger et al., 2008)
has examined whether TCDD-mediated liver toxicity can be
mediated by the AHR in the absence of DNA binding.
The AHR exist in the cytoplasm as a core tetrameric
complex, composed of the ligand-binding subunit, a dimer of
hsp90, the X-associated protein 2 (also referred to as ARA9 or
AIP), and p23 (reviewed in Petrulis and Perdew, 2002). The
hsp90 and XAP2 are considered a chaperone complex that
stabilizes the AHR in the cytoplasm, protecting it from
proteolysis and helping the receptor maintain its ligand-binding
conformation. Upon binding an agonist, a conformational
change in the AHR occurs that allows access to its nuclear
localization sequence, and the receptor rapidly translocates into
the nucleus. In the nucleus, ARNT appears to cause
displacement of hsp90, leading to the formation of the AHR/
ARNT complex, which can then bind to dioxin-responsive
elements (DRE) and regulate many of the receptor’s target
genes. Some of these targets include phase I drug metabolism
genes such as CYP1A1, CYP1B1, and CYP1A2. The
transcription of several important phase II enzymes, such as
UGT1A1 and NADPH-quinone reductase, are also directly
regulated by the AHR through DRE. The AHR also regulates
genes with diverse functions such as p27
Kip1, epiregulin,
IGFBP-1, and Bax.
Establishment of ahr-null mouse models has revealed that
most, if not all, of the toxic effects of TCDD are mediated
through the activation of the AHR (Fernandez-Salguero et al.,
1996). The lack of AHR expression leads to lower reproductive
success, reduced life span, immunological defects, and reduced
liver size (Abbott et al., 1999; Rodriguez-Sosa et al., 2005;
Schmidt et al., 1996). The mechanism mediating the reduced
liver size appears to be smaller hepatocytes and a portosystemic
shunting of blood due to a persistent fetal vascular structure
(Lahvis et al., 2000). Through the use of microspheres, the
portal blood ﬂow that bypasses the ahr-null liver was calculated
to be about 50% (Lahvis et al.,2 0 0 0 ) .U s i n gahr
fx/fx mice and
Cre-lox technology, where the AHR was selectively disrupted in
either hepatocytes or endothelial cells, revealed that the deletion
of AHR expression in endothelial cells leads to a lack of
developmental closure of the ductus venosus (Walisser et al.,
2005). Furthermore, TCDD-mediated hepatotoxicity requires the
expression of the AHR in hepatocytes.
Several research groups have performed DNA microarray
studies on liver after exposure to an AHR ligand. In these
experiments a large number of genes exhibit increases in
messenger RNA (mRNA) levels, while interestingly an equal
number of genes demonstrated a decrease in mRNA levels.
These results would suggest that the AHR could both increase
and decrease transcriptional levels of various genes after ligand
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transcription are primary effects, then the AHR appears to be
able to directly downregulate gene transcription of a subset of
genes. Considering all the possible mechanisms that could be
utilized by the AHR to inﬂuence gene transcription, it is
a daunting task to determine which mechanism is responsible
for the change in transcription of a gene that does not appear to
have a functional DRE immediately upstream of its transcrip-
tional start site.
The AHR could alter gene transcription through several
different mechanisms, which are depicted in Figure 1. The ﬁrst
possible mechanism is through the binding of the AHR/ARNT
heterocomplex to its cognate response element, and this is the
mechanism that is most often studied. The second mechanism
is the ability of the AHR/ARNT heterocomplex to bind to other
transcription factors and modulate their ability to alter
transcriptional activity. This could occur through the ability
of the AHR/ARNT complex to block recruitment of a tran-
scription factor to an enhancer/promoter region or through
binding to a transcription factor at the promoter. A third distinct
mechanism that has been considered is the possibility that the
AHR in the cytoplasm is capable of binding to other proteins
and modulating their activity, such as evidence for activation of
c-src upon dissociation from the AHR cytoplasmic complex
after ligand binding (Park et al., 2007). Similar studies with
nuclear hormone receptors suggest that such mechanisms need
not be mutually exclusive, thus further increasing the level of
complexity associated with AHR signaling and toxicity. The
Bradﬁeld laboratory has decided to tackle this issue through the
development of genetically altered mouse lines that express
mutant forms of the AHR with distinct characteristics. The ﬁrst
line was made using homologous recombination to introduce
a mutation in the nuclear localization sequence, which is also
part of the DNA-binding domain (Bunger et al., 2003). These
mice, designated as Ahr
nls/nls, express an AHR that fails to
translocate into the nucleus, bind to its cognate response
element, or induce cytochrome P-450 enzymatic activity.
However, this mutant retained its ability to bind to hsp90,
XAP2, and ligand. Treatment of Ahr
nls/nls mice with TCDD
revealed that the mutant AHR mice did not exhibit any change
in liver or thymus weight, which is seen in Ahr
þ/þ mice. This
mouse model would indicate that TCDD-mediated hepatotox-
icity requires the AHR to be present in the nucleus.
Bradﬁeld et al. developed a second mouse model that
expresses an AHR mutant designated Ahr
dbd/dbd. The AHR in
this mouse model is capable of translocating into the nucleus
and heterodimerizing with ARNT, yet is incapable of binding
a DRE (Bunger et al., 2008). The actual mutation introduced
into the Ahr-coding sequence was the addition of a glycine and
serine between the arginine-39 and aspartate-40 residues.
Expression of the AHR-dbd failed to enhance DRE-driven
transcriptional activity. While this mutant AHR is capable of
binding to hsp90 and ligand, its expression in cells leads to
a constitutive localization in the nucleus. This would suggest
that changes in the structure of the AHR near the NLS
apparently leads to recognition by the nuclear translocation
machinery. Despite nuclear localization and its ability to
heterodimerize with ARNT, the TCDD-AHR-dbd complex
failed to mediate cleft palate, hydronephrosis, thymic in-
volution, or hepatomegaly. Several investigators have hypoth-
esized that part of the toxicity of TCDD may be through the
ability of an highly activated AHR to sequester ARNT away
from its other partners (e.g., HIF1a). Results obtained with the
AHR-dbd–expressing mice would support the concept that
sequestration of ARNT is not a major factor in the toxicities
tested. Thus, both the Ahr
nls/nls and Ahr
dbd/dbd mouse model
ﬁrmly support the concept that overt toxicities mediated by
TCDD exposure requires DRE-driven transcriptional activity.
The development of a mouse that expresses a DNA-binding
mutant AHR goes well beyond its use in TCDD-mediated
toxicity studies. This mouse model may be particularly
important in determining whether the AHR/ARNT heterodimer
in the nucleus is capable of altering gene transcription through
protein-protein interacting events, leading to nontoxic pheno-
typic end points. This nonclassical mechanism of transcription
factor/receptor function has been demonstrated with nuclear
receptors (e.g., ER, AR) that can modulate transcription
through mechanisms other than binding to their cognate
DNA response element. This type of activity in the nucleus
can be mediated by several distinct mechanisms. However,
there appears to be two main mechanisms, with the ﬁrst being
the binding of one transcription factor (TF) to another, leading
to inhibition of the activity of one of the TFs; this can be
termed the ‘‘sequestration’’ mechanism. The second mecha-
nism involves tethering of one TF to another that is bound to
its cognate DNA response element in a speciﬁc enhancer/
FIG. 1. Five possible distinct mechanisms of AHR function that could lead
to altered gene transcription. (1) Cytoplasmic protein-binding events; (2) AHR
sequesters and blocks another transcription factor’s ability to bind to its cognate
response element; (3) AHR binds as a monomer to a transcription factor bound
to its cognate response element; (4) AHR/ARNT binds to a transcription factor
bound to its cognate response element; and (5) AHR/ARNT bind to a DRE.
302 PERDEWpromoter region; this can be termed ‘‘transrepression.’’ One of
the best illustrations of promoter tethering is the transrepression
of certain NF-jB–regulated genes by the glucocorticoid
receptor (GR) (Luecke and Yamamoto, 2005). To further
explore the tethering activity of the GR, a point mutant in the
GR-A458T was knocked into the GR gene using the Cre/loxP
system in mice (Reichardt et al., 1998). This GR mutant fails to
dimerize in the presence of dexamethasone and thus fails to
recognizeglucocorticoidreceptorresponseelement.Interestingly,
these mice survive and are fertile, in contrast to GR-null mice
that die shortly after birth. The transrepression response was
demonstrated to occur with several genes and known to be
repressed after dexamethasone treatment, in these mutant GR
mice. Another example is the ability of the estrogen receptor
to mediate transrepression of the RelA (Valentine et al.,
2000). The ER can also tether to the AhR/ARNT heterodimer
at the CYP1A1 promoter (Beischlag and Perdew, 2005).
Conversely, recruitment of the AhR/ARNT heterodimer to
ERa in MCF-7 on the pS2 promoter results in a repression of
pS2 mRNA levels in the presence of estrogen and the AHR
ligand 3-MC (Ohtake et al., 2003). How widespread the level
of gene modulation by the AhR through non-DRE–mediated
mechanisms has not been explored. In addition, it is not clear
whether the AhR alone can modulate transcription as described
for the monomeric GR or if the AhR must heterodimerize with
ARNTtoexhibit thistypeofactivity.Futurestudiesutilizing the
mutant AHR mouse models developed by the Bradﬁeld
laboratory should shed light on the multiple mechanisms of
gene regulation mediated by the AHR.
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